Search results
Showing 8151 to 8200 of 8236 results
Keep the size of your waist to less than half of your height, NICE recommends
People are being encouraged to keep their waist measurement to less than half their height to reduce the risk of potential health problems.
Consultation on updated guideline to assess and prevent falls in older people
We're seeking views from healthcare professionals and the public on draft recommendations covering assessments and interventions to reduce the risk of falls in older people.
For the first time, we have recommended a targeted treatment option for ALK-positive non-small-cell lung cancer, to be given after surgery to reduce the risk of the disease coming back.
Consultation on NHS England proposals for a phased launch of obesity injection
Proposals for a phased launch of the obesity injection tirzepatide have been set out, as a consultation begins.
Today (1 October 2024) NICE is consulting on draft guidance that does not recommend elacestrant for treating a type of advanced breast cancer.
NICE Board says new method allowing greater weight to be given to severe diseases is working
At today's meeting (25th September 2024) our board has concluded that the new severity modifier is working as intended.
Adults with Von Hippel-Lindau disease to benefit from new treatment
NICE has recommended belzutifan for some adults with Von Hippel-Lindau disease, in final draft guidance, which could benefit up to 100 people.
Thousands could benefit from new option for treating symptoms of uterine fibroids
As many as 30,000 adults could benefit from a new treatment for moderate to severe symptoms of uterine fibroids after we published final guidance today (14 August 2024) recommending linzagolix.
Patients in England with severe beta-thalassaemia will be amongst the first in Europe to benefit from one-time gene therapy exagamglogene autotemcel.
14,000 women at risk of fractures after the menopause to benefit from bone disease drug
Over 14,000 people to benefit after NICE published final guidance recommending abaloparatide as an option for treating osteoporosis after menopause, if there is a very high risk of fracture.
Daiichi Sankyo and partner company AstraZeneca have been unwilling to offer a price that would enable NICE to recommend Enhertu as cost effective for the NHS in final guidance published today.
Thousands of people could benefit from a new oral hormone therapy for advanced hormone sensitive prostate cancer.
NICE recommends digital technology to help diagnose ADHD in children and young people
A digital technology that will help healthcare professionals provide a quicker diagnosis to people with attention deficit hyperactivity disorder (ADHD) can be used by the NHS, NICE has said in draft guidance.
New study shows NICE Advice support can reduce appraisal timelines by 3 months
Companies who receive scientific advice from our NICE Advice service may experience a faster path to guidance publication, a study has found.
Our updated guideline to improve the diagnosis of endometriosis
The guideline makes new recommendations and updates existing ones on diagnosing and managing a condition that affects approximately 1.5 million women of reproductive age in the UK.
Updated menopause guidance includes discussion aid to support conversations about HRT
Our updated guideline on menopause emphasises the importance of an individualised approach and shared decision-making when making choices about treatment for symptoms.
More people are benefitting from NICE-recommended statins to reduce heart attacks and strokes
Around 5.3 million people in England were given a NICE-recommended statin or ezetimibe by their GP to help reduce their cholesterol during 2023/24, the largest number on record and almost 900,000 more than in 2022/23.
Hundreds of people with multiple myeloma could receive a new, targeted treatment recommended for use within the Cancer Drugs Fund today (Tuesday, 29 October).
Heart failure patients to be remotely monitored by technology shown to cut hospitalisations by 50%
Two technologies, HeartLogic and TriageHF, have been recommended in final diagnostic guidance.
Draft guidance issued for consultation recommends the use of 4 AI technologies to help professionals detect fractures in urgent care settings.
New Alzheimer's treatment donanemab does not currently demonstrate value for the NHS says NICE
More evidence is needed on the clinical and cost-effectiveness of donanemab, a new treatment for mild Alzheimer’s disease.
NICE recommends new treatment to prevent and reduce hearing loss in people being treated for cancer
For the first time, NICE has recommended an innovative new treatment to help stop babies, children and young people who are undergoing cancer treatment from losing their hearing.
Over 1000 people with advanced breast cancer set to benefit from new once-a-day tablet
We’ve issued final draft guidance recommending a new once-a-day tablet that is set to benefit around 1,100 people with a type of advanced breast cancer.
Public consultation launched on changes to NICE's Highly Specialised Technologies routing criteria
NICE is proposing changes to its routing criteria for Highly Specialised Technologies (HST) to ensure more consistent, predictable and transparent decisions.
New price deal paves way for NICE approval of treatment for rare genetic condition
A new treatment for Duchenne muscular dystrophy (DMD) is set to be available to around 1,700 people in England following positive final draft guidance from NICE published today.
For the first time, the British Thoracic Society (BTS), National Institute for Health and Care Excellence (NICE) and the Scottish Intercollegiate Guidelines Network (SIGN) have collaborated to develop a UK-wide asthma guideline.
NICE responds to failure of talks to reach price agreement on Enhertu
Talks with the makers of Enhertu have ended without agreement, meaning guidance that does not recommend Enhertu for advanced breast cancer will remain unchanged.
Towards a new partnership – NICE and the voluntary and community sector
Victoria Thomas gives details of NICE’s new voluntary and community sector forum.
"Tell me and I forget. Teach me and I remember. Involve me and I learn." Benjamin Franklin.
More people with rare genetic disorder eligible for nusinersen
Following a review of data collected as part of the Managed Access Agreement, more people with spinal muscular atrophy (SMA) are to benefit from nusinersen.
Public consultation on updates to health technology evaluations manual
A public consultation marking the first update to NICE's health technology evaluations manual is now open.
NICE issues draft guidance for public consultation which does not recommend Evusheld for preventing COVID-19 in some adults.
Hundreds of children with type 2 diabetes to be offered choice of two life changing technologies
Children with type 2 diabetes who currently manage their condition with the stressful task of finger prick testing several times a day could be offered a choice between two ‘life changing’ technologies to virtually automate the process.
NICE recommends life changing technology is rolled out to people with type 1 diabetes
Thousands of people with type 1 diabetes could be offered wearable technology to help them manage their condition following the publication of final draft guidance by NICE.
NICE recommends genetic test to prevent newborn babies going deaf
A genetic test to establish if a newborn baby is vulnerable to deafness if treated with a commonly used antibiotic has been recommended by NICE in final guidance.
Draft guidance recommends healthcare professionals ask people about gambling
Health professionals should ask people about gambling if they attend a health check or GP appointment with a mental health problem, in a similar way to how people are asked about their smoking and alcohol consumption, according to new draft guidance.
Jeanette Kusel explains how we are working in partnership to improve patient access to the best digital health innovations.
NICE partners with international health technology assessment bodies
Six health technology assessment (HTA) bodies from three continents are to collaborate on a range of topics that will benefit people accessing healthcare around the world.
Thousands of appointments released for the NHS without compromising safety
Delivering fewer radiotherapy sessions over a shorter period of time, first introduced during COVID, benefits patients and the system long-term
New life-extending drug treatment for children and teenagers with an aggressive form of brain cancer
Dabrafenib with trametinib is a targeted treatment that can be taken at home rather than hospital and improves the length and quality of life for patients..
Updated guideline recommends more treatment choices for menopause symptoms
New evidence shows that cognitive behavioural therapy (CBT) can help reduce menopause symptoms including hot flushes and night sweats, depressive symptoms and problems sleeping NICE has said in its draft updated guideline on menopause published today (17 November 2023).
NICE and the GetReal Institute: facilitating the adoption and implementation of real-world evidence in health care decision-making.
Three treatments for COVID-19 recommended in final draft guidance
Everyone with COVID-19 at highest risk of developing severe disease will have access to clinically and cost-effective treatments.
Starting with the end in mind - the Innovative Licensing and Access Pathway
The Innovative Licensing and Access Pathway (ILAP) will smooth the process by which innovative new medicines are developed, speeding their progression from clinical trial through to the NHS, bringing significant benefits to patients.
A 'safe space' for addressing complex health technology assessment challenges
Nick Crabb discusses how we’re developing a collaborative space for research and development, to help us create new methods and processes for health technology assessment.
170,000 people in England to have further treatment choice for preventing migraine attacks
In final draft guidance published today NICE has recommended atogepant, the first of a new type of oral treatment option for preventing both chronic and episodic migraines, opening the way for up to 170,000 people to choose it on the NHS in England.
Around 4,000 people with sickle cell disease could benefit from a new treatment recommended by NICE
Improved deal signals NICE recommendation of sickle cell treatment voxelotor.
More evidence needed to recommend Type 2 diabetes treatment tirzepatide
More evidence is needed on the clinical and cost-effectiveness of a new treatment option for people with type 2 diabetes before it could be recommended for NHS use
Around 100,000 fewer colonoscopies expected to take place each year
Tens of thousands of people a year could be spared the need for a colonoscopy following new guidance from NICE.
New treatment option recommended for people with type 2 diabetes
Around 180,000 people with difficult to manage type 2 diabetes could benefit from tirzepatide as new treatment option for type 2 diabetes.